Clinical research is rapidly advancing in using psychedelic drugs to treat opioid addiction. However, psychedelics can also reduce opioid-related deaths as a SUBSTITUTE for opioids.
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
Compass Pathways acquires an unspecified IP portfolio of psychedelic and emphathogenic substances.
Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline
Wesana looks to expand its TBI-based psychedelics research into MDMA, with a new research partnership with MAPS.
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
Atai affiliate, Perception Neuroscience is commencing a Phase 2a clinical trial of an R-ketamine medication for the treatment of depression.
Why Psychedelic Medicine Cures Will Have Greater Profit Potential Than Big Pharma Bandaids
Big Pharma's business model for drug development is all about maximizing profits, not health. Psychedelic medicine can maximize profits AND health.
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
Atai Life Sciences seeks to integrate digital therapeutics into ketamine-based treatment for TRD, via its digital therapeutic platform, Introspect Digital Therapeutics.
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
Psychedelics media star, Hamilton Morris is joining Compass Pathways as a full-time consultant on psychedelics research.
Wesana Health Announces Closing of PsyTech Acquisition
Wesana Health closes on its acquisition of PsyTech, solidifying its business model as it seeks a U.S. listing.
Novamind Uplists to OTCQB Venture Market
Novamind commences formal trading on the OTCQB under the symbol "NVMDF".
Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104
Field Trip will focus on Treatment-Resistant Depression and Postpartum Depression as indications for drug development of FT-104.
Psychedelic Stocks Chasing Medical Treatment Markets With Combined Value Of $330B
Two BILLION people with untreated mental health disorders is a lot of market potential. We attach some numbers to these treatment markets.
Psyched Wellness Commences Neurobehavioral Preclinical Trial Study on AME-1
Psyched Wellness moves a step closer to commencing its Phase I clinical trial on AME-1. The company is still targeting commercialization for 2022.
